EVOLVE-205

N/A

Report date: 2026/03/23 20:03:44

First In Class

Base Information

Drug NameEVOLVE-205

Drug Alias NameEVOLVE205EVOLVE-205

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionAnti-CD20Anti-CD2

TargetsB-lymphocyte antigen CD20T-cell surface antigen CD2

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesEvolveImmune Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesEvolveImmune Therapeutics Inc

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A